pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,337 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT819Endpoints616BioPharma Dive237onclive165Fierce Biotech84BioSpace83raps32globenewswire health26
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Obamacare rolls shrank dramatically in many states over the past year, new federal data shows
    States across the country saw steep drops in the number of people covered by the Affordable Care Act over the past year, according to new federal data.
    STAT · 23d ago↗ source
  • STAT+: Online GLP-1 prescriptions are often fast, easy — and low on clinical oversight
    A new secret-shopper study found that GLP-1 prescriptions from telehealth sites aren't often backed by appropriate clinical care.
    STAT · 23d ago↗ source
  • Gene editing developer Scribe plots an IPO
    The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.
    BioPharma Dive · 23d ago↗ source
← prev
page 18 of 54
next →
fda press21
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Novartis to acquire ADC developer in a deal worth up to $1.5B
    The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
    BioPharma Dive · 23d ago↗ source
  • STAT+: Four major biotech updates to catch up on
    Anthropic CEO talks drug discovery, Medicare proposes steep 340B drug payment cuts, and more biotech news
    STAT · 23d ago↗ source
  • Cancer, immune drugmakers dominate VC funding so far in 2026
    Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so far in 2026, per BioPharma Dive data.
    BioPharma Dive · 23d ago↗ source
  • Beyond Boston: Unlikely cities stake biotech claims
    As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
    BioPharma Dive · 23d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
    Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio
    STAT · 23d ago↗ source
  • The race for an Ebola therapy begins
    Male marathoners "hit the wall," mental health in 2026, and more Morning Rounds news
    STAT · 23d ago↗ source
  • Opinion: The smart way to regulate the peptide boom
    “The FDA should pursue a structured, clinician-guided framework” on popular peptides, writes former surgeon general Jerome Adams.
    STAT · 24d ago↗ source
  • Opinion: Stopping doctors from ordering unnecessary diagnostic tests requires a structural fix
    “The medical industry has spent enormous effort making more advanced tests but expended little effort learning how to use tests correctly,” writes Daniel Morgan.
    STAT · 24d ago↗ source
  • STAT+: GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse
    Supporters say clinical trial diversity is about making sure drugs and devices work, not about DEI.
    STAT · 24d ago↗ source
  • STAT+: I spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learned
    Call AI in biotech hype at your peril. There are real reasons that pharmaceutical companies are embracing this technology right now.
    STAT · 24d ago↗ source
  • What does content creation do to mental health?
    This year at Vidcon, I was struck by how much of the conference’s programming was dedicated to the mental health of content creators.
    STAT · 24d ago↗ source
  • STAT+: Medicare takes another swing at 340B cuts to hospitals
    Reducing Medicare payments for 340B drugs is the latest proposal focused on the hotly debated drug discount program.
    STAT · 27d ago↗ source
  • STAT+: Lawmakers urge HHS to force Eli Lilly to provide 340B drug discounts to hospitals
    Lawmakers step into a dispute between Eli Lilly and hospitals about the 340b drug discount program.
    STAT · 27d ago↗ source
  • STAT+: Elevance sues government over $115 million tied to Medicare Advantage star ratings
    The health insurer says CMS didn't calculate its star ratings appropriately.
    STAT · 27d ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.
    STAT · 27d ago↗ source
  • STAT+: What does DeGette’s loss mean for pharma?
    Colorado Democratic Rep. Diana DeGette, who lost her primary, was knowledgeable about biopharma, if not always a friend to the industry.
    STAT · 27d ago↗ source
  • A PureTech startup banks $180M for a new IPF drug
    Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
    BioPharma Dive · 27d ago↗ source
  • Roche KRAS drug succeeds in head-to-head lung cancer study
    The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
    BioPharma Dive · 27d ago↗ source
  • STAT+: Roche drug sets new standard for KRAS-driven lung cancer
    Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout
    STAT · 27d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a court win for Amgen, Novo seeking supplier discounts, and more
    U.S. judge blocked a Colorado state panel from placing a cap on the price of Amgen's blockbuster drug Enbrel
    STAT · 27d ago↗ source
  • STAT+: U.S. judge blocks Colorado’s first-of-its-kind price cap on an Amgen drug
    A federal judge blocked a Colorado state panel from placing a cap on the price of Enbrel, a blockbuster drug sold by Amgen
    STAT · 27d ago↗ source
  • STAT+: More frequent, more intense, and longer heat waves pose health risks for Americans
    The presidential fitness test is back, surprising new data on the health risks of obesity, and more Morning Rounds news
    STAT · 28d ago↗ source